Springer Science & Business Media, Jul 31, 2002 - Medical - 145 pages
Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Correcting anemia slows renal disease progression
Does treatment with EPO improve RBC survival?
Has the best route of administration for epoetin been established?
Is renal anemia management determined by science or reimbursement regulations?
When does anemia impact the heart in chronic kidney disease?
Improvements in anemia management with darbepoetin alfa a new erythropoiesis stimulating protein
Normalizing hematocrit in renal failure dangerous or desirable?
Do race gender or mode of dialysis modulate erythropoietin response?
Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever?
Is secondary hyperparathyroidism a significant cause of renal anemia?
Is longterm intravenous iron therapy risky?
Anemia and erythropoietin therapy in kidney transplant recipients where are the data?
Intravenous iron treatment a comparison of available drugs
Are uremic inhibitors of erythropoiesis clinically relevant?
Other editions - View all
ACEI administration anemia management anemia of chronic anemic angiotensin associated Besarab bone marrow cardiovascular chronic renal failure CKD patients Clin correction of anemia darbepoetin alfa dextran diabetic drug effect efficacy end-stage renal disease endogenous erythropoietin EPO dose epoetin erythropoiesis stimulating protein erythropoietin levels erythropoietin therapy ESRD ESRD patients ferritin g/dl hematocrit hematocrit level hemodialysis patients hemoglobin concentration hemoglobin levels improved increase intravenous iron iron dextran iron sucrose JAm Soc Nephrol kidney disease Kidney Int kidney transplant kidney transplant recipients left ventricular hypertrophy Macdougall marrow fibrosis Nephrol Dial Transplantation Nephrology normal hematocrit Novel erythropoiesis stimulating Onyekachi Ifudu outcomes parathyroid hormone parathyroidectomy patients with chronic patients with CKD peritoneal dialysis peritoneal dialysis patients pharmacokinetic pre-dialysis rBuEPO receptor recombinant erythropoietin recombinant human erythropoietin renal anemia renal function renal insufficiency renal transplantation response to EPO response to erythropoietin rHuBPO secondary hyperparathyroidism sodium ferric gluconate subcutaneous target hemoglobin uremia week